About MediSieve
MediSieve is a company based in London (United Kingdom) founded in 2014 by George Frodsham. MediSieve has raised $4.18 million across 5 funding rounds from investors including UK Research and Innovation, European Union and 24 Haymarket. The company has 12 employees as of September 30, 2021. MediSieve offers products and services including MediSieve System, AAV Gene Therapy Enabler, IL-6 Driven Hyperinflammation Treatment, and Severe Malaria Treatment. MediSieve operates in a competitive market with competitors including Haemonetics, Vetex Medical, Immutrix Therapeutics, Hemostasis and Immunocept Medical Products, among others.
- Headquarter London, United Kingdom
- Employees 12 as on 30 Sep, 2021
- Founders George Frodsham
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Medisieve Ltd
- Date of Incorporation 08 Apr, 2014
- Jurisdiction LONDON, ENGLAND
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.18 M (USD)
in 5 rounds
-
Latest Funding Round
$2.14 M (USD), Series A
Jun 23, 2021
-
Investors
UK Research and Innovation
& 3 more
-
Employee Count
12
as on Sep 30, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of MediSieve
MediSieve offers a comprehensive portfolio of products and services, including MediSieve System, AAV Gene Therapy Enabler, IL-6 Driven Hyperinflammation Treatment, and Severe Malaria Treatment.
Purifies blood by removing pathogens with magnetic beads.
Depletes antibodies to facilitate novel gene therapies.
Treats hyperinflammation by depleting specific cytokines.
Removes infected cells to manage severe malaria cases.
People of MediSieve
Unlock access to complete
Unlock access to complete
Funding Insights of MediSieve
MediSieve has successfully raised a total of $4.18M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $2.14 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in MediSieve
MediSieve has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include UK Research and Innovation, European Union and 24 Haymarket.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech focused VC firm investing in the UK
|
Locked | Locked | Locked | |
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Research and innovation funding is managed for UK advancement.
|
Locked | Locked | Locked |
Investor details for MediSieve
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MediSieve
Investment portfolio details for MediSieve
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - MediSieve
Detailed financials for MediSieve
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Medisieve Comparisons
Peer comparison for MediSieve
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of MediSieve
MediSieve operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Haemonetics, Vetex Medical, Immutrix Therapeutics, Hemostasis and Immunocept Medical Products, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Hematology products and solutions are provided for medical applications.
|
|
| Locked | Locked | Locked |
Catheters for venous clot management and removal are developed.
|
|
| Locked | Locked | Locked |
Blood cleansing treatment device
|
|
| Locked | Locked | Locked |
Develops and manufactures hemostatic products for surgical bleeding control and patient care.
|
|
| Locked | Locked | Locked |
Blood filtration therapy for severe sepsis is developed.
|
Detailed competitors of MediSieve
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Medisieve
Complete news archive for MediSieve
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MediSieve
MediSieve was founded in 2014 and raised its 1st funding round 3 years after it was founded.
MediSieve is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
George Frodsham is the current CEO of MediSieve. They have also founded this company.
MediSieve is a funded company, having raised a total of $4.18M across 5 funding rounds to date.
As of Sep 30, 2021, the latest employee count at MediSieve is 12.
MediSieve was founded in 2014 in London, United Kingdom, and operates in the biotechnology sector. Magnetic blood filtration solutions are developed by the company to remove infected cells, pathogens, toxins, and viruses from blood. The Medisieve device integrates peristaltic haemofiltration pumps with antibody-coated magnetic particles, targeting specific cells or antigens for treating blood-borne diseases. Operations focus on therapeutic applications in healthcare.
MediSieve's top competitors include Haemonetics, Vetex Medical and Immutrix Therapeutics.
MediSieve offers MediSieve System, AAV Gene Therapy Enabler, IL-6 Driven Hyperinflammation Treatment, and Severe Malaria Treatment.
MediSieve has 4 investors. Key investors include UK Research and Innovation, European Union, 24 Haymarket, and EIC Fund.